Aspergillosis Pipeline Product - Research and Development 2017 Aspergillosis - Pipeline Review, H1 2017 | Page 2

The report reviews latest news related to pipeline therapeutics for Aspergillosis. Direct Purchase
This Report at http://www.reportsnreports.com/purchase.aspx?name=1010786 .
Report helps to Gain strategically significant competitor information, analysis, and insights to
formulate effective R&D strategies. Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage. Identify and
understand important and diverse types of therapeutics under development for Aspergillosis.
Identify potential new clients or partners in the target demographic. Develop strategic initiatives by
understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by
identifying key players and it’s most promising pipeline therapeutics. Devise corrective measures for
pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and scope. Modify the
therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline
List of Tables
























Global Markets Direct Report Coverage
Aspergillosis - Overview
Aspergillosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aspergillosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aspergillosis - Companies Involved in Therapeutics Development
Mechanism Of Action
R&D Progress
Aspergillosis - Dormant Projects
Aspergillosis - D iscontinued Products
Aspergillosis - Product Development Milestones
Featured News & Press Releases
May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal
During its Research and Development Day
Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to
Chief Medical Officer
Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID
Annual Meetings
Jan 09, 2017: F2G Receives European Orphan Drug Designation for its Lead Candidate F901318